SI-BONE (NASDAQ:SIBN) Shares Down 4.5% – Time to Sell?

SI-BONE, Inc. (NASDAQ:SIBN) shares traded down 4.5% during trading on Monday . The company traded as low as $12.81 and last traded at $12.77. 38,819 shares were traded during mid-day trading, a decline of 89% from the average session volume of 362,545 shares. The stock had previously closed at $13.37.

Analyst Upgrades and Downgrades

SIBN has been the subject of a number of research analyst reports. Needham & Company LLC boosted their target price on SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price target on shares of SI-BONE in a report on Tuesday, February 25th. Finally, Truist Financial restated a “buy” rating and set a $22.00 price objective (up from $18.00) on shares of SI-BONE in a report on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SI-BONE currently has an average rating of “Buy” and a consensus price target of $24.40.

SI-BONE Stock Performance

The stock has a market capitalization of $552.74 million, a P/E ratio of -14.15 and a beta of 1.02. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The stock has a 50 day simple moving average of $15.65 and a two-hundred day simple moving average of $14.64.

SI-BONE (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The firm had revenue of $49.00 million for the quarter, compared to analyst estimates of $48.87 million. On average, equities analysts forecast that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

Insider Activity at SI-BONE

In other news, SVP Michael A. Pisetsky sold 3,128 shares of SI-BONE stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total transaction of $44,229.92. Following the completion of the sale, the senior vice president now owns 244,878 shares of the company’s stock, valued at approximately $3,462,574.92. This trade represents a 1.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Anthony J. Recupero sold 3,311 shares of SI-BONE stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total transaction of $46,850.65. Following the completion of the sale, the insider now owns 284,555 shares of the company’s stock, valued at $4,026,453.25. This trade represents a 1.15 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,776 shares of company stock worth $96,644. Company insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On SI-BONE

Several institutional investors and hedge funds have recently added to or reduced their stakes in SIBN. Charter Oak Capital Management LLC acquired a new position in shares of SI-BONE during the 1st quarter worth $337,000. Rhumbline Advisers lifted its holdings in shares of SI-BONE by 3.6% in the first quarter. Rhumbline Advisers now owns 59,721 shares of the company’s stock worth $838,000 after acquiring an additional 2,100 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of SI-BONE by 20,352.6% in the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company’s stock valued at $55,000 after purchasing an additional 3,867 shares in the last quarter. Paradigm Capital Management Inc. NY grew its holdings in shares of SI-BONE by 5.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,386,031 shares of the company’s stock valued at $19,432,000 after purchasing an additional 69,831 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in SI-BONE by 8.3% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,666 shares of the company’s stock worth $1,439,000 after purchasing an additional 7,855 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.